Program
hetrombopag olamine
Also written as “Hetrombopag Olamine”, “Herombopag Olamine Tablets” and “Hetrombopag Olamine Tablet”.
Its studies are mostly in Anemia, Aplastic · Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Jul 18, 201715 company-led studies, 4 open or runningNext primary completion: Dec 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 154 open or running | phase 3since Jul 18, 2017 | Dec 25, 2012 | Dec 2028phase 3 · NCT07286032 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 25, 2012First study: phase 1 study in HealthyFirst studyNCT01830660 · 96 enrolled · China
- Mar 20, 2015Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT02403440 · 24 enrolled · China
- Apr 1, 2015Phase 1 study in HealthyNCT02409394 · 12 enrolled · China
- Nov 19, 2015Phase 1 study in Chronic Idiopathic Thrombocytopenic PurpuraNCT02614846 · 29 enrolled · China
- Jul 18, 2017Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT03222843 · 424 enrolled · China
- Jun 3, 2018Phase 2 study in Anemia, AplasticNCT03557099 · 55 enrolled · China
- Jun 18, 2018Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT03603132 · 15 enrolled · China
- Jan 30, 2019Phase 3 study in Anemia, AplasticNCT03825744 · 240 enrolled · China
- May 5, 2019Phase 1 study in HealthyNCT03977805 · 6 enrolled · China
- Jul 12, 2021Phase 3 study in Treatment-naive Severe Aplastic AnemiaNCT04961710 · 157 enrolled · China
- Oct 12, 20212 phase 1 studies in Sever Aplastic AnaemiaNCT05088655, NCT05088642
- Sep 1, 2023Phase 1 study in Adult Patients With Chronic Primary ITPNCT06062680 · 15 planned
- Mar 29, 2024Phase 1 study in Adult Patients With Chronic Primary ITPNCT06346925 · 18 planned · China
- Dec 10, 2025Phase 3 study in Patients With Chemotherapy-Induced ThrombocytopeniaNCT07286032 · 150 planned · United States, Bulgaria, China and more
Ahead
- Dec 2028Primary completion: phase 3 study in Patients With Chemotherapy-Induced ThrombocytopeniaNCT07286032
TargetBeta
MPL →read by rule
“Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| romiplostimrule | Amgen | phase 4 | 38 |
| avatrombopagrule | Eisai | phase 4 | 25 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07286032Patients With Chemotherapy-Induced Thrombocytopenia · United States, Bulgaria, China and more | 3 | Recruiting | Dec 2028 | 150 |
| NCT06346925Adult Patients With Chronic Primary ITP · China | 1 | Not yet recruiting | Jul 2024 | 18 |
| NCT06062680Adult Patients With Chronic Primary ITP | 1 | Not yet recruiting | Nov 15, 2023 | 15 |
| NCT05088655Sever Aplastic Anaemia · China | 1 | Completed | Jul 25, 2022 | 58 |
| NCT05088642Sever Aplastic Anaemia · China | 1 | Completed | Dec 4, 2020 | 24 |
| NCT04961710Treatment-naive Severe Aplastic Anemia · China | 3 | Active, not recruiting | Nov 30, 2024 | 157 |
| NCT03977805Healthy · China | 1 | Completed | Jun 13, 2019 | 6 |
| NCT03825744Anemia, Aplastic · China | 3 | Completed | Jul 3, 2024 | 240 |
| NCT03603132Purpura, Thrombocytopenic, Idiopathic · China | 1 | Completed | Aug 17, 2018 | 15 |
| NCT03557099Anemia, Aplastic · China | 2 | Completed | Oct 31, 2019 | 55 |
| NCT03222843Purpura, Thrombocytopenic, Idiopathic · China | 3 | Completed | Nov 11, 2019 | 424 |
| NCT02614846Chronic Idiopathic Thrombocytopenic Purpura · China | 1 | UNKNOWN | Mar 2016 | 29 |
| NCT02409394Healthy · China | 1 | Completed | Apr 2014 | 12 |
| NCT02403440Purpura, Thrombocytopenic, Idiopathic · China | 1 | UNKNOWN | Apr 2015 | 24 |
| NCT01830660Healthy · China | 1 | Completed | Jun 2013 | 96 |
How it is read
Names in the registry
- “Hetrombopag Olamine”, 9 entries
- “Herombopag Olamine Tablets”, 2 entries
- “Hetrombopag Olamine Tablet”, 2 entries
- “Hetrombopag Olamine+Standard Therapy”, 1 entry
- “Hetrombopag Olamine Tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Aplastic, 5 studies
- Purpura, Thrombocytopenic, Idiopathic, 4 studies
- Thrombocytopenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.